Italy Drug & Device Rules for 2026 Trials
Decision brief
Answer first · skim in under a minute
This report highlights critical updates on drug and medical device litigation laws in Italy for 2026, focusing on clinical trials and their implications.
Italy’s 2026 drug and medical device litigation risk sits inside EU law, not a standalone local playbook. Sponsors must align clinical-trial authorisations with Regulation (EU) 536/2014 and device obligations with MDR 2017/745 while Italian authorities supervise on the ground.
Contents9 sections
Key Takeaways
- Clinical trials of medicines in Italy follow Regulation (EU) No 536/2014 and CTIS submission rules.
- CTR became applicable on 31 January 2022, replacing Directive 2001/20/EC for new applications after transition.
- Medical devices fall under Regulation (EU) 2017/745 (MDR), with national registration still relevant during Eudamed transition.
- Litigation exposure rises when protocol conduct, safety reporting, or device claims diverge from these EU texts.
What EU clinical-trial rules apply in Italy in 2026?
Italy authorises and supervises medicinal clinical trials as an EU Member State under the Clinical Trials Regulation. The legal text is Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use.
The regulation’s stated aim is a harmonised assessment and supervision process with high participant-safety standards and transparency through publication of authorisation and results information. Primary text: EUR-Lex Regulation (EU) 536/2014.
How does CTIS change Italian trial operations?
Sponsors submit clinical trial applications through the Clinical Trials Information System managed by EMA, while Member States retain authorisation and supervision responsibility.
For multinational protocols that include Italian sites, Part I and Part II assessment timelines, substantial modifications, and safety reporting must follow CTR processes rather than legacy national-only dossiers. EMA overview: EMA Clinical Trials Information System.
What medical-device rules drive Italian product risk?
Device manufacturers and importers placing products on the Italian market must meet MDR obligations under Regulation (EU) 2017/745, including clinical evaluation, post-market surveillance, and vigilance.
- CE marking and conformity assessment routes under MDR
- Economic-operator responsibilities for importers and distributors
- Clinical evidence proportionate to device risk class
Legal text: EUR-Lex Regulation (EU) 2017/745 (MDR). Commission clinical-trials policy context remains useful for medicine/device combination products: European Commission clinical trials page.
Where do litigation and compliance pressures usually arise?
Private litigation and public enforcement often track documentation gaps: informed consent, protocol deviations, delayed SUSAR reporting, promotional claims beyond the SmPC or device IFU, and incomplete clinical evaluation reports.
Pharma legal teams should treat CTR transparency publications and MDR PMS/vigilance files as discovery-relevant records, not only regulatory filings. Cross-border trials amplify exposure when Italian site conduct differs from the authorised CTIS dossier.
What remains unproven in “2026 litigation report” narratives?
Secondary legal-market reports may claim rising Italian case counts or new local statutes. Without a primary court or ministry dataset cited here, those volume claims are not treated as fact.
What is verifiable from EU primary law is the operating system: CTR + CTIS for trials, MDR for devices. Investment and compliance plans should start there, then layer Italy-specific fee, ethics-committee, and reimbursement rules from national instruments.
Related NovaPharma coverage
Frequently Asked Questions
Which EU law now governs medicinal clinical trials in Italy?
Regulation (EU) No 536/2014, the Clinical Trials Regulation, governs the authorisation and supervision of medicinal product clinical trials across the EU/EEA, including Italy, via the Clinical Trials Information System (CTIS).
When did the Clinical Trials Regulation become applicable?
The Clinical Trials Regulation became applicable on 31 January 2022. After the transition, new initial clinical trial applications are submitted through CTIS rather than under the old Directive 2001/20/EC national routes.
What EU rule set covers medical devices sold in Italy?
Medical devices in the EU, including Italy, are primarily governed by Regulation (EU) 2017/745 (MDR). National databases may still be used while Eudamed modules complete rollout.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
